Calmodulin mutations affecting Gly114 impair binding to the NaV1.5 IQ-domain

Missense variants in CALM genes encoding the Ca2+-binding protein calmodulin (CaM) cause severe cardiac arrhythmias. The disease mechanisms have been attributed to dysregulation of RyR2, for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) and/or CaV1.2, for Long-QT Syndrome (LQTS). Rece...

Full description

Saved in:
Bibliographic Details
Main Authors: Malene Brohus (Author), Ana-Octavia Busuioc (Author), Reinhard Wimmer (Author), Mette Nyegaard (Author), Michael Toft Overgaard (Author)
Format: Book
Published: Frontiers Media S.A., 2023-08-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_6bfc5c715c5a4efd9f52bd4c9705ffb5
042 |a dc 
100 1 0 |a Malene Brohus  |e author 
700 1 0 |a Ana-Octavia Busuioc  |e author 
700 1 0 |a Reinhard Wimmer  |e author 
700 1 0 |a Mette Nyegaard  |e author 
700 1 0 |a Michael Toft Overgaard  |e author 
245 0 0 |a Calmodulin mutations affecting Gly114 impair binding to the NaV1.5 IQ-domain 
260 |b Frontiers Media S.A.,   |c 2023-08-01T00:00:00Z. 
500 |a 1663-9812 
500 |a 10.3389/fphar.2023.1210140 
520 |a Missense variants in CALM genes encoding the Ca2+-binding protein calmodulin (CaM) cause severe cardiac arrhythmias. The disease mechanisms have been attributed to dysregulation of RyR2, for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) and/or CaV1.2, for Long-QT Syndrome (LQTS). Recently, a novel CALM2 variant, G114R, was identified in a mother and two of her four children, all of whom died suddenly while asleep at a young age. The G114R variant impairs closure of CaV1.2 and RyR2, consistent with a CPVT and/or mild LQTS phenotype. However, the children carrying the CALM2 G114R variant displayed a phenotype commonly observed with variants in NaV1.5, i.e., Brugada Syndrome (BrS) or LQT3, where death while asleep is a common feature. We therefore hypothesized that the G114R variant specifically would interfere with NaV1.5 binding. Here, we demonstrate that CaM binding to the NaV1.5 IQ-domain is severely impaired for two CaM variants G114R and G114W. The impact was most severe at low and intermediate Ca2+ concentrations (up to 4 µM) resulting in more than a 50-fold reduction in NaV1.5 binding affinity, and a smaller 1.5 to 11-fold reduction at high Ca2+ concentrations (25-400 µM). In contrast, the arrhythmogenic CaM-N98S variant only induced a 1.5-fold reduction in NaV1.5 binding and only at 4 µM Ca2+. A non-arrhythmogenic I10T variant in CaM did not impair NaV1.5 IQ binding. These data suggest that the interaction between NaV1.5 and CaM is decreased with certain CaM variants, which may alter the cardiac sodium current, INa. Overall, these results suggest that the phenotypic spectrum of calmodulinopathies may likely expand to include BrS- and/or LQT3-like traits. 
546 |a EN 
690 |a calmodulin 
690 |a calmodulinopathy 
690 |a arrhythmogenic 
690 |a cardiac ion-channel regulation 
690 |a calmodulin target binding 
690 |a experimental variant interpretation 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Frontiers in Pharmacology, Vol 14 (2023) 
787 0 |n https://www.frontiersin.org/articles/10.3389/fphar.2023.1210140/full 
787 0 |n https://doaj.org/toc/1663-9812 
856 4 1 |u https://doaj.org/article/6bfc5c715c5a4efd9f52bd4c9705ffb5  |z Connect to this object online.